{
    "clinical_study": {
        "@rank": "161475", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, open-label, single arm study will evaluate the safety and efficacy of\n      subcutaneously administered RoActemra/Actemra (tocilizumab) in patients with active\n      rheumatoid arthritis who are either na\u00efve to or have an inadequate response to prior\n      non-biologic or/and biologic DMARDs. Patients will receive RoActemra/Actemra 162 mg\n      subcutaneously weekly as monotherapy or in combination with methotrexate or other\n      non-biologic DMARDs for 24 weeks. Depending on response, patients will either continue\n      treatment with RoActemra/Actemra and discontinue methotrexate/non-biologic DMARDs or\n      continue combination treatment with RoActemra/Actemra and methotrexate/non-biologic DMARDs\n      for a further 28 weeks, or discontinue RoActemra/Actemra treatment."
        }, 
        "brief_title": "A Study of Subcutaneously Administered RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Diagnosis of active rheumatoid arthritis according to the revised (1987) ACR criteria\n             or EULAR/ACR (2010) criteria\n\n          -  Either naive to MTX and/or other non-biologic DMARD treatment or having inadequate\n             response (inefficacy/intolerance) to previous non-biologics, and/or having inadequate\n             response (inefficacy/intolerance) to previous biologic DMRADs (including Tumor\n             necrosis factor inhibitors or Abatacept when this was assigned as first-line\n             biologic)\n\n          -  Oral corticosteroids (</= 10 mg/day prednisolone or equivalent) and non-steroidal\n             anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if\n             on a stable dose regimen for >/= 4 weeks prior to baseline\n\n          -  Permitted non biologic DMARDs are allowed if a stable dose for at least 4 weeks prior\n             ro baseline\n\n          -  Receiving treatment on an output basis, not including RoActemra/Actemra (tocilizumab)\n\n          -  Females of childbearing potential must agree to use a reliable means of contraception\n             during the study; females of childbearing potential must use a reliable means of\n             contraception for at least 3 month following the last dose of RoActemra/Actemra\n\n        Exclusion Criteria:\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned\n             major surgery within 6 months following baseline\n\n          -  Rheumatic autoimmune disease other than RA; secondary Sj\u00f6gren's syndrome with RA is\n             permitted\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status in\n             Rheumatoid Arthritis\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of\n             16\n\n          -  Prior history of or current inflammatory joint disease other than RA\n\n          -  Exposure to tocilizumab (either IV or SC) at any time prior to baseline\n\n          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the\n             investigational drug, whichever is longer) of screening\n\n          -  Previous treatment with any cell-depending therapies\n\n          -  Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline\n\n          -  History of severe allergic or anaphylactic reactions to human, humanized, or murine\n             monoclonal antibodies\n\n          -  Evidence of serious uncontrolled concomitant cardiovascular, nervous system,\n             pulmonary, renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or\n             gastrointestinal disease\n\n          -  Known active current or history of recurrent bacterial, viral, fungal, mycobacterial,\n             or other infections\n\n          -  Any major episode of infection requiring hospitalization of treatment with IV\n             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of\n             screening\n\n          -  Active TB requiring treatment within the previous 3 years\n\n          -  Positive for hepatitis B surface or hepatitis C infection\n\n          -  Primary or secondary immunodeficiency (history of or currently active)\n\n          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10\n             years (except for basal and squamous cell carcinoma of the skin or carcinoma in situ\n             of the cervix uteri that has been excised and cured) , or breast cancer diagnosed\n             within the previous 20 years\n\n          -  Pregnancy or breast feeding women\n\n          -  Neuropathies or other conditions that interfere with pain evaluation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941095", 
            "org_study_id": "ML28695", 
            "secondary_id": "2013-000359-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "RoActemra/Actemra", 
                "description": "162 mg SC weekly", 
                "intervention_name": "tocilizumab [RoActemra/Actemra]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "RoActemra/Actemra", 
                "description": "Permitted non-biologic disease-modifying antirheumatic drugs, at a stable dose that was initiated at least 4 weeks prior to baseline, are: azathioprine, chloroquine, hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine. Treatment is according to standard of care.", 
                "intervention_name": "DMARD", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antirheumatic Agents", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "115 27"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Athens", 
                        "country": "Greece", 
                        "zip": "11527"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haidari", 
                        "country": "Greece", 
                        "zip": "124 62"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heraklion", 
                        "country": "Greece", 
                        "zip": "711 10"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ioannina", 
                        "country": "Greece", 
                        "zip": "455 00"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Larissa", 
                        "country": "Greece", 
                        "zip": "411 10"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Patras", 
                        "country": "Greece", 
                        "zip": "265 04"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece", 
                        "zip": "544 65"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thessaloniki", 
                        "country": "Greece", 
                        "zip": "546 42"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Greece"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter, Open-label, Phase IIIb Study to Evaluate the Safety, Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-biologic Disease-modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28695 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Greece: Ministry of Health"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients achieving clinical remission as measured by Disease Activity Score 28 (DAS28) < 2.6 at Week 24", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients who maintain DAS28 remission/low disease activity from Week 24 to Week 52 on RoActemra/Actemra monotherapy", 
                "safety_issue": "No", 
                "time_frame": "From Week 24 to Week 52"
            }, 
            {
                "measure": "Proportion of patients who achieve DAS28 remission/low disease activity  up to Week 52 for patients with intensification of methotrexate/non-biologic DMARDs in combination with RoActemra/Actemra since Week 24 to Week", 
                "safety_issue": "No", 
                "time_frame": "From Week 24 to Week 52"
            }, 
            {
                "measure": "Change in American College of Rheumatology (ACR) scores", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 52"
            }, 
            {
                "measure": "Change in European League Against Rheumatism (EULAR) criteria", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 52"
            }, 
            {
                "measure": "Change in Simplified/Clinical Disease Activity Index (SDAI/CDAI)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 52"
            }, 
            {
                "measure": "Change in Tender/Swollen Joint Count (TJC/SJC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 52"
            }, 
            {
                "measure": "Proportion of patients with corticosteroid reduction/discontinuation", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "60 weeks"
            }, 
            {
                "measure": "Incidence of anti-tocilizumab antibodies", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Soluble interleukin-6 receptor (sIL-6R) levels", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Pharmacokinetics: Plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "Patient reported outcomes: Global Assessment/Pain visual analogue scales (PGA/Pain-VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI)", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}